vs
Side-by-side financial comparison of National Vision Holdings, Inc. (EYE) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $487.3M, roughly 1.0× National Vision Holdings, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 0.7%, a 6.1% gap on every dollar of revenue. On growth, National Vision Holdings, Inc. posted the faster year-over-year revenue change (7.9% vs -1.7%). Over the past eight quarters, National Vision Holdings, Inc.'s revenue compounded faster (7.6% CAGR vs -0.1%).
Vision Research is an international company that manufactures high-speed digital cameras based in Wayne, New Jersey. Their cameras are marketed under the Phantom brand, and are used in a broad variety of industries including: defense, industrial product development, manufacturing, automotive, scientific research, and entertainment. Vision Research is a business unit of the Materials Analysis Division of Ametek Inc., a global manufacturer of electronic instruments and electromechanical devices.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
EYE vs MD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $487.3M | $493.8M |
| Net Profit | $3.4M | $33.7M |
| Gross Margin | — | — |
| Operating Margin | 2.0% | 9.9% |
| Net Margin | 0.7% | 6.8% |
| Revenue YoY | 7.9% | -1.7% |
| Net Profit YoY | 139.8% | 10.5% |
| EPS (diluted) | $0.04 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $493.8M | ||
| Q3 25 | $487.3M | $492.9M | ||
| Q2 25 | $486.4M | $468.8M | ||
| Q1 25 | $510.3M | $458.4M | ||
| Q4 24 | $437.3M | $502.4M | ||
| Q3 24 | $451.5M | $511.2M | ||
| Q2 24 | $451.7M | $504.3M | ||
| Q1 24 | $482.8M | $495.1M |
| Q4 25 | — | $33.7M | ||
| Q3 25 | $3.4M | $71.7M | ||
| Q2 25 | $8.7M | $39.3M | ||
| Q1 25 | $14.2M | $20.7M | ||
| Q4 24 | $-28.6M | $30.5M | ||
| Q3 24 | $-8.5M | $19.4M | ||
| Q2 24 | $-3.1M | $-153.0M | ||
| Q1 24 | $11.7M | $4.0M |
| Q4 25 | — | 9.9% | ||
| Q3 25 | 2.0% | 13.8% | ||
| Q2 25 | 3.4% | 12.8% | ||
| Q1 25 | 5.1% | 7.0% | ||
| Q4 24 | -5.8% | 7.8% | ||
| Q3 24 | -2.0% | 6.6% | ||
| Q2 24 | 0.1% | -31.3% | ||
| Q1 24 | 4.9% | 3.2% |
| Q4 25 | — | 6.8% | ||
| Q3 25 | 0.7% | 14.5% | ||
| Q2 25 | 1.8% | 8.4% | ||
| Q1 25 | 2.8% | 4.5% | ||
| Q4 24 | -6.5% | 6.1% | ||
| Q3 24 | -1.9% | 3.8% | ||
| Q2 24 | -0.7% | -30.3% | ||
| Q1 24 | 2.4% | 0.8% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | $0.04 | $0.84 | ||
| Q2 25 | $0.11 | $0.46 | ||
| Q1 25 | $0.18 | $0.24 | ||
| Q4 24 | $-0.36 | $0.37 | ||
| Q3 24 | $-0.11 | $0.23 | ||
| Q2 24 | $-0.04 | $-1.84 | ||
| Q1 24 | $0.15 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $375.2M |
| Total DebtLower is stronger | $236.5M | $570.5M |
| Stockholders' EquityBook value | $858.8M | $865.9M |
| Total Assets | $2.0B | $2.2B |
| Debt / EquityLower = less leverage | 0.28× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $375.2M | ||
| Q3 25 | $56.0M | $340.1M | ||
| Q2 25 | $48.5M | $224.7M | ||
| Q1 25 | $80.0M | $99.0M | ||
| Q4 24 | $73.9M | $229.9M | ||
| Q3 24 | $81.2M | $103.8M | ||
| Q2 24 | $179.5M | $19.4M | ||
| Q1 24 | $150.1M | $8.0M |
| Q4 25 | — | $570.5M | ||
| Q3 25 | $236.5M | $577.2M | ||
| Q2 25 | $255.6M | $583.9M | ||
| Q1 25 | $244.7M | $590.5M | ||
| Q4 24 | $248.6M | $597.1M | ||
| Q3 24 | $252.8M | — | ||
| Q2 24 | $143.9M | — | ||
| Q1 24 | $448.6M | — |
| Q4 25 | — | $865.9M | ||
| Q3 25 | $858.8M | $890.7M | ||
| Q2 25 | $850.6M | $833.8M | ||
| Q1 25 | $836.2M | $789.2M | ||
| Q4 24 | $816.3M | $764.9M | ||
| Q3 24 | $840.0M | $732.5M | ||
| Q2 24 | $843.4M | $706.5M | ||
| Q1 24 | $841.3M | $856.2M |
| Q4 25 | — | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.0B | $2.1B | ||
| Q1 25 | $2.0B | $2.0B | ||
| Q4 24 | $2.0B | $2.2B | ||
| Q3 24 | $2.0B | $2.1B | ||
| Q2 24 | $2.1B | $2.0B | ||
| Q1 24 | $2.2B | $2.2B |
| Q4 25 | — | 0.66× | ||
| Q3 25 | 0.28× | 0.65× | ||
| Q2 25 | 0.30× | 0.70× | ||
| Q1 25 | 0.29× | 0.75× | ||
| Q4 24 | 0.30× | 0.78× | ||
| Q3 24 | 0.30× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $46.6M | $114.1M |
| Free Cash FlowOCF − Capex | $30.3M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 3.4% | — |
| Cash ConversionOCF / Net Profit | 13.83× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $83.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $114.1M | ||
| Q3 25 | $46.6M | $137.3M | ||
| Q2 25 | $54.3M | $137.2M | ||
| Q1 25 | $32.2M | $-117.5M | ||
| Q4 24 | $30.3M | $133.0M | ||
| Q3 24 | $27.9M | $91.8M | ||
| Q2 24 | $51.5M | $107.0M | ||
| Q1 24 | $24.0M | $-125.2M |
| Q4 25 | — | — | ||
| Q3 25 | $30.3M | — | ||
| Q2 25 | $42.4M | — | ||
| Q1 25 | $12.0M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $31.9M | — | ||
| Q1 24 | $4.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | 6.2% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | -0.4% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 7.1% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 7.3% | — | ||
| Q3 24 | 5.3% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 4.1% | — |
| Q4 25 | — | 3.39× | ||
| Q3 25 | 13.83× | 1.91× | ||
| Q2 25 | 6.22× | 3.49× | ||
| Q1 25 | 2.27× | -5.66× | ||
| Q4 24 | — | 4.36× | ||
| Q3 24 | — | 4.72× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.05× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EYE
Segment breakdown not available.
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
